🤔 Should NICE reconsider its cost-effectiveness thresholds?

In our latest blog post, we jump into the ongoing debate surrounding NICE’s approach to quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs).

We explore the implications of static thresholds in a changing economic landscape, and highlight the importance of dynamic evaluations in healthcare technology assessment. Join the discussion and uncover how these insights could shape future healthcare decisions.

#SyenzaNews #HealthEconomics #costeffectiveness #HealthcareInnovation #MarketAccess

💊 How can access to essential medications change lives?

Our latest article looks into the significant strides made in South Africa regarding access to Trikafta for cystic fibrosis patients.

Thanks to the initiatives by Vertex Pharmaceuticals reviewed by the Competition Commission, many patients can now obtain this critical medication more affordably. This is an important advancement in ensuring equitable healthcare access.

Read more about how these efforts are enhancing patient accessibility and the impact of Section 21 authorizations!

#SyenzaNews #pharmaceuticals #MarketAccess #HealthcareInnovation

🧪 Curious about the potential of **imlunestrant** in treating advanced breast cancer?

The recent Phase 3 EMBER-3 study provides groundbreaking insights into its efficacy and safety, especially in conjunction with the CDK4/6 inhibitor abemaciclib. With significant improvements in progression-free survival for patients with ESR1 mutations, this research represents a promising advancement in oncology treatment options. Dive into the details and learn how this all-oral regimen could enhance patient compliance and treatment outcomes!

#SyenzaNews #oncology #drugdevelopment #innovation #clinicaltrials